| Literature DB >> 25050654 |
Jimmy T Efird1, Wesley T O'Neal2, Stephen W Davies3, Jason B O'Neal4, Linda C Kindell5, Curtis A Anderson6, W Randolph Chitwood7, T Bruce Ferguson8, Alan P Kypson9.
Abstract
Mortality represents an important outcome measure following coronary artery bypass grafting. Shorter survival times may reflect poor surgical quality and an increased number of costly postoperative complications. Quality control efforts aimed at increasing survival times may be misleading if not properly adjusted for case-mix severity. This paper demonstrates how to construct and cross-validate efficiency-outcome plots for a specified time (e.g., 6-month and 1-year survival) after coronary artery bypass grafting, accounting for baseline cardiovascular risk factors. The application of this approach to regional centers allows for the localization of risk stratification rather than applying overly broad and non-specific models to their patient populations.Entities:
Mesh:
Year: 2014 PMID: 25050654 PMCID: PMC4113888 DOI: 10.3390/ijerph110707470
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Patient characteristics (N = 4639).
| Characteristic | 2001–2002 | 2003–2004 | 2005–2006 | 2007–2008 | PTrend |
|---|---|---|---|---|---|
| Overall | 1574 (13) | 1147 (9) | 984 (8) | 934 (7) | - |
| Age, Mean ± SD | 64 ± 11 | 64 ± 10 | 64 ± 10 | 63 ± 10 | 0.23 † |
| Male Sex | 1094 (70) | 812 (71) | 712 (72) | 695 (74) | 0.0062 * |
| White Race | 1268 (81) | 923 (80) | 785 (80) | 709 (76) | 0.010 * |
| BMI (mg/kg2), Mean ± SD | 29 ± 5.6 | 30 ± 5.9 | 30 ± 5.8 | 30 ± 5.9 | 0.23 † |
| Elective Surgery | 706 (45) | 741 (65) | 466 (47) | 382 (41) | 0.0050 |
| CAD Severity | 103 (7) | 75 (7) | 53 (5) | 76 (8) | 0.18 †† |
| 387 (25) | 294 (26) | 228 (23) | 254 (27) | ||
| 1084 (69) | 778 (68) | 703 (71) | 604 (65) | ||
| Left Main Disease | 280 (18) | 284 (25) | 343 (35) | 245 (26) | <0.0001 * |
| Recent Smoker | 424 (27) | 356 (31) | 301 (31) | 322 (34) | 0.0001 * |
| Hypertension | 1220 (78) | 886 (77) | 805 (82) | 832 (89) | <0.0001 * |
| Diabetes | 592 (38) | 436 (38) | 368 (37) | 405 (43) | 0.017 * |
| Heart Failure | 251 (16) | 312 (27) | 296 (30) | 236 (25) | <0.0001 * |
| Dialysis | 36 (2) | 16 (1) | 17 (2) | 26 (3) | 0.53 * |
| PAD | 199 (13) | 173 (15) | 179 (18) | 166 (18) | <0.0001 * |
| COPD | 96 (6) | 201 (18) | 199 (20) | 245 (26) | <0.0001 * |
| Prior Stroke | 107 (7) | 99 (9) | 84 (9) | 93 (10) | 0.0067 * |
| Prior MI | 691 (44) | 541 (47) | 455 (46) | 470 (50) | 0.0043 * |
| Prior PCI | 307 (19) | 257 (22) | 244 (25) | 238 (25) | 0.0001 * |
* Cochran-Armitage Trend Test; † Linear Regression; †† Chi-square Test for non-zero Correlation. BMI = body mass index; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; MI = myocardial infarction; PAD = peripheral arterial disease; PCI = percutaneous coronary intervention; SD = standard deviation.
Postoperative complications (N = 4639).
| Complication | 2001–2002 | 2003–2004 | 2005–2006 | 2007–2008 | PTrend * |
|---|---|---|---|---|---|
| Myocardial Infarction | 3 (<1) | 3 (<1) | 3 (<1) | 3 (<1) | 0.49 |
| Stroke | 23 (1) | 27 (2) | 11 (1) | 11 (1) | 0.30 |
| ARDS | 25 (2) | 23 (2) | 9 (1) | 3 (<1) | 0.0023 |
| Pneumonia | 27 (2) | 31 (3) | 26 (3) | 17 (2) | 0.65 |
| Renal Failure | 32 (2) | 38 (3) | 27 (3) | 11 (1) | 0.27 |
| Operative Mortality | 46 (3) | 41 (4) | 25 (3) | 13 (1) | 0.018 |
* Cochran-Armitage Trend Test; ARDS = acute respiratory distress syndrome.
Figure 1Efficiency-Outcome (EO) plot of risk-adjusted survival at six months *.
Figure 2Efficiency-Outcome (EO) plot of risk-adjusted survival at one year *.
C-statistic and 95% confidence interval.
| Year Period | Number of | Number of | Number of | C-Statistic |
|---|---|---|---|---|
| 2001–2002 | 82,566 | 593,780 | 258,786 | 0.70 (0.62–0.77) |
| 2003–2004 | 324,328 | 214,520 | 109,798 | 0.66 (0.55–0.77) |
| 2005–2006 | 141,552 | 105,692 | 35,860 | 0.75 (0.59–0.88) |
| 2007–2008 | 88,635 | 60,128 | 28,507 | 0.68 (0.48–0.85) |
| 2001–2010 | 4,934,832 | 3,659,189 | 1,275,643 | 0.74 (0.69–0.79) |
CI = confidence interval.
Differential cross-validation (model performance) for survival estimates.
| Characteristic (Levels) | % Within Equivalence Region | ||||
|---|---|---|---|---|---|
| 2001–2002 | 2003–2004 | 2005–2006 | 2007–2008 | 2001–2008 | |
| Age (<65, ≥65) | 100 * | 100 * | 100 * | 100 * | 100 * |
| Sex (Male, Female) | 100 * | 85 †† | 100 * | 94 * | 100 * |
| Race (Black, White) | 100 * | 100 * | 100 * | 100 * | 100 * |
| CAD Severity (1, ≥2 vessels) | 100 * | 100 * | 100 * | 100 * | 100 * |
| Hypertension (Yes, No) | 100 * | 100 * | 100 * | 100 * | 100 * |
| Heart Failure (Yes, No) | 100 * | 76 †† | 100 * | 100 * | 100 * |
| Prior Stroke (Yes, No) | 100 * | 94 * | 100 * | 100 * | 100 * |
* p > 0.05; † p ≤ 0.05; †† p < 0.01. CAD = coronary artery disease.
Test for interaction effects by time.
| Characteristic | 2001–2002 | 2003–2004 | 2005–2006 | 2007–2008 | 2001–2008 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| χ2 | χ2 | χ2 | χ2 | χ2 | ||||||
| Age | 0.25 | 0.62 | 0.32 | 0.57 | 0.19 | 0.66 | 0.32 | 0.57 | 0.0007 | 0.98 |
| Sex | 1.05 | 0.31 | 7.18 | 0.0074 | 8.1 | 0.0044 | 2.8 | 0.095 | 6.93 | 0.0085 |
| Race | 3.0 | 0.084 | 0.85 | 0.36 | 1.4 | 0.24 | 0.0 | 0.99 | 2.23 | 0.14 |
| 2-vessel CAD | 0.13 | 0.72 | 0.29 | 0.59 | 0.042 | 0.84 | 0.25 | 0.62 | 0.052 | 0.82 |
| 3-vessel CAD | 0.28 | 0.60 | 0.17 | 0.68 | 0.69 | 0.41 | 0.043 | 0.84 | 0.53 | 0.47 |
| Hypertension | 0.038 | 0.85 | 1.2 | 0.28 | 0.012 | 0.91 | 3.1 | 0.079 | 0.035 | 0.85 |
| Heart Failure | 0.089 | 0.76 | 3.9 | 0.048 | 0.042 | 0.84 | 1.1 | 0.29 | 2.24 | 0.13 |
| Prior Stroke | 0.17 | 0.68 | 0.089 | 0.77 | 0.26 | 0.61 | 1.7 | 0.19 | 0.22 | 0.64 |
| All Covariates | 5.22 | 0.73 | 22 | 0.0046 | 12 | 0.16 | 9.1 | 0.33 | 15.84 | 0.045 |
χ2 = Chi-Square; CAD = coronary artery disease.